About fennec pharmaceuticals - FENC
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
FENC At a Glance
Fennec Pharmaceuticals, Inc.
Research Triangle Park
Durham, North Carolina 27709
| Phone | 1-919-636-4530 | Revenue | 44.64M | |
| Industry | Biotechnology | Net Income | -9,741,000.00 | |
| Sector | Health Technology | Employees | 35 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
FENC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.929 |
| Price to Book Ratio | 7.416 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -29.171 |
| Enterprise Value to Sales | 4.105 |
| Total Debt to Enterprise Value | N/A |
FENC Efficiency
| Revenue/Employee | 1,275,485.714 |
| Income Per Employee | -278,314.286 |
| Receivables Turnover | 1.922 |
| Total Asset Turnover | 0.773 |
FENC Liquidity
| Current Ratio | 6.374 |
| Quick Ratio | 6.225 |
| Cash Ratio | 3.498 |
FENC Profitability
| Gross Margin | 91.568 |
| Operating Margin | -14.072 |
| Pretax Margin | -21.583 |
| Net Margin | -21.82 |
| Return on Assets | -16.864 |
| Return on Equity | -65.818 |
| Return on Total Capital | -27.461 |
| Return on Invested Capital | -40.871 |
FENC Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |